The meeting is scheduled to be held on Thursday, November 05, 2026. The primary agenda for the meeting is:
- To consider and approve the Unaudited financial results (Standalone & Consolidated) for the quarter and half year ended September 30, 2026.
- To consider any other matter with the permission of the Chair.
Regarding the trading window closure, the company refers to its earlier communication dated September 28, 2026. The trading window for dealing in the company's securities has been closed since October 01, 2026 and will remain closed until 48 hours after the declaration of the aforementioned unaudited financial results.
This intimation has also been made available on the company's website at www.molbiodiagnostics.com in compliance with Regulation 46 of the SEBI LODR Regulations.